Embla, Denmark’s leading provider of sustainable weight management solutions, is excited to announce its expansion into the UK market. Embla’s mission is to help people achieve greater weight loss results faster and more sustainably than ever before by providing personalised, transformative support combining the latest in modern medicine, health coaching, and digital tools.

Embla is a CQC registered health-tech start-up, which has raised a seed round of €3,500,000 from Crowberry and VentureFriends bringing the total raised capital to €4,000,000. Their pre-seed investor Founders also participated alongside 8 angels including Jad Antoun, CEO of Huspy, Daniel Bakh and Dorin Tarau co-founders of Fullview. With more than 4,000 users and over 1,000 active members to their weight management program, Embla members are losing an average of 15% of their body weight after 7 months. Embla have collected more than 300,000 real-world data points and counting that can be leveraged to create digital obesity therapeutics.

The company’s expansion into the UK comes at a time when the nation continues to see its population struggle with the challenges of sustainable weight loss. However, the development of new medications, that when combined with wraparound support services produce very impressive results, indicate real grounds for optimism amongst obesity sufferers.

In the 2021 survey from the House Commons Library showed a total of 63.8% of British people were either overweight or obese. Men were more likely than women to be overweight or obese (68.6% of men compared with 59.0% of women).
By personalising the entire journey and customising medication dosages to the specific needs of each member, 98% of Embla members are using 60% less medication than the pharmaceutical guidelines, Embla is able to effectively address weight-related issues as well as alleviate the stress placed on the National Health Service.

Embla is on the rise, after securing seed funding in August, the company has been surging ahead, leading to early plans for a strong Series A-round investment in mid-2023. Get ready for even more exciting things to come.

“We are thrilled to be bringing our successful weight management program to the UK, and are looking forward to helping people living with obesity in the UK achieve their weight loss goals in a healthy and sustainable way,” said Nicholas Syhler, Co-Founder of Embla. “Our program is based on the latest research and is tailored to the needs of each member, making it one of the most effective and sustainable weight loss programs available today.”

Hekla Arnardóttir partner at Partner at Crowberry Capital who started her career with an Icelandic health-tech scale-up joined the Embla team as a seed investor, “The combination of new medication and innovative digital tools opens up a path for more effective treatment for people that want support on their weight loss journey.”
Apostolos Apostolakis, an entrepreneur turned investor and partner at VentureFriends VC, invested in Embla. He has invested and supported a large number of startups with a focus on consumer software and marketplaces. “We are very excited to support Embla and have been impressed by Nicholas and Laust’s uncompromising focus on delivering long term results for the Embla members.”

Simon Sylvest from Founders, joined the Embla team as a pre-seed investor. “It’s been a privilege to invest in Embla to drive change in obesity, with a personalised approach, improving access and quality of care for hundreds of members. The traditional “exercise more and eat less” advice is outdated. Embla aims to help with its holistic weight management program and I am very happy that Embla is now available in the UK.”

The Embla weight management programme is revolutionising the way individuals combat obesity and the associated health risks. By customising medication dosages to the specific needs of each member, they are able to effectively achieve weight loss goals, as well reduce their chances of developing obesity-related diseases such as diabetes, heart disease, and high blood pressure – which in turn helps alleviate the stresses placed on the National Health Service.